- Conditions
- Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease, Dementia Alzheimer Type, Mild Alzheimer&Amp;Amp;#39;s Disease, Moderate Alzheimer&Amp;Amp;#39;s Disease, Alzheimer&Amp;#39;s Disease (AD), Alzheimer&Amp;#39;s Dementia
- Interventions
- TMS, Transcranial Magnetic Stimulation Sham
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 55 Years to 100 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Alzheimer's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 10, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Alzheimer's Disease studies are organized in the registry
The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Live official records
Open in full search- Conditions
- Down Syndrome-Associated Alzheimer's Disease (DS-AD)
- Interventions
- Mivelsiran, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Maitland, Florida • Naples, Florida
- Conditions
- Alzheimer Disease, Early Onset, Dementia, Alzheimer Disease
- Interventions
- Device Implantation- Boston Scientific, VERCISE GENUS™ system, DBS Stimulation - Boston Scientific, VERCISE GENUS™ system
- Procedure · Device
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Alzheimer Disease
- Interventions
- AMDX-2011P
- Drug
- Lead sponsor
- Amydis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Alzheimer Disease
- Interventions
- Donanemab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 185
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 146 more
- Conditions
- Alzheimer Disease, Lymphatic Obstruction
- Interventions
- Symani Surgical System
- Device
- Lead sponsor
- MMI (Medical Microinstruments, Inc.)
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Jacksonville, Florida • Buffalo, New York
- Conditions
- Healthy, Dementia, Alzheimer Disease, Physical Activity
- Interventions
- Physical Activity Condition
- Behavioral
- Lead sponsor
- University of North Carolina, Greensboro
- Other
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Greensboro, North Carolina
- Conditions
- Cognition Disorders
- Interventions
- Placebo, Solanezumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 1,169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 47 more
- Conditions
- Arterial Stiffness, White Matter Lesions, Cognitive Decline
- Interventions
- S-equol, Placebo
- Drug
- Lead sponsor
- Akira Sekikawa
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 369 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
- Interventions
- NAV4694
- Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 48 more
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Senicapoc, Placebo Tablet
- Drug · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Sacramento, California • Walnut Creek, California
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder
- Interventions
- Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
About this Alzheimer's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.